The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Preliminary results of a phase II/III clinical study of the TLR9 agonist MGN1703 in patients with advanced colorectal carcinoma with disease control after first-line therapy: IMPACT study.
M. Schmidt
Employment or Leadership Position - MOLOGEN
H. Schmoll
No relevant relationships to disclose
F. Mayer
No relevant relationships to disclose
J. Riera
No relevant relationships to disclose
G. Hapke
No relevant relationships to disclose
J. Andel
No relevant relationships to disclose
D. Nitsche
No relevant relationships to disclose
R. Ziebermayr
No relevant relationships to disclose
E. Weith
No relevant relationships to disclose
M. Schroff
Employment or Leadership Position - MOLOGEN
M. Tschaika
Employment or Leadership Position - MOLOGEN
B. Wittig
Consultant or Advisory Role - MOLOGEN